Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon and Boehringer Ingelheim Enter Oncology Research Service Collaboration

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
Five year collaboration will support Boehringer Ingelheim’s drug discovery programs.

Horizon Discovery Ltd (Horizon) has announced that it has signed a research service collaboration agreement with Boehringer Ingelheim.

Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimization and pre-clinical stages to elucidate their anti-cancer properties and help guide drug discovery programs.

Under the terms of the collaboration, Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, and will provide an FTE and access to its custom cell line generation services to support the programs.

Horizon will also apply its proprietary genome editing technology GENESIS™ to develop human isogenic disease model cell lines, according to Boehringer Ingelheim’s specifications.

Using GENESIS, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably and without unwanted and confounding genotypes and/or phenotypes. The resulting high quality cell lines accurately model the disease-causing mutations found in patients.

Kam Dhaliwal, Vice President of Sales, Horizon, said “We are delighted that Boehringer Ingelheim has selected Horizon as a partner for its drug discovery programs, in recognition of the value our X-MAN cell lines and drug discovery services can add to the search for novel treatments for cancer."

Financial terms of the agreement were not disclosed.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Appoints Dr David Smoller as an Executive Director
Company announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
Monday, November 03, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Discovery Adds Three Eminent CRISPR Experts to its SAB
Dr. Emmanuelle Charpentier, Dr. J. Keith Joung, and Dr. Feng Zhang join the Company’s panel of expert gene editing advisors.
Tuesday, August 05, 2014
Horizon and OPDC Sign Collaboration Agreement
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.
Friday, July 25, 2014
Horizon Licenses AAV Gene Delivery Technology from Stanford University
Agreement supplements existing exclusive rAAV gene targeting license from University of Washington.
Thursday, July 03, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery Licenses CRISPR Gene Editing Technology
The Company announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Thursday, June 12, 2014
Horizon Completes Acquisition of CombinatoRx from Zalicus
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.
Monday, June 02, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon Licenses CRISPR/Cas9 Gene Editing Technology from ERS Genomics
Horizon has entered into a non-exclusive license agreement with ERS.
Saturday, May 10, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Discovery and Transgenomic Collaborate
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.
Thursday, January 16, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
New Mechanism of Plant RNA Degradation Identified
Researchers have identified a novel mechanism by which RNA is degraded.
Enlisting Insects to Protect Agriculture
New program aims for insect delivery of protective genes to modify mature plants within a single growing season.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos